We use DNA nanotechnology to fight cancer.
The challenge
If cancer cells cannot be recognized by one antigen exclusively, T-cell engaging therapies can lead to on-target off-tumor reactions with severe side-effects.
The Solution
LOGIBODY (LOGIc-gated antiBODY) – a switch for antibody immunotherapies. This ultra-miniaturized nanoswitch made from DNA can specifically recognize cancer cells. The increased specificity allows the immune system to fight cancer in a targeted manner and leads to lower activity on healthy tissue.
The Team
-
Dr. Klaus Wagenbauer
FOUNDER & CEO
-
Dr. Benjamin Kick
FOUNDER & COO
-
Dr. Jonas Funke
FOUNDER & CSO
-
Dr. Andrea Neuner
SENIOR SCIENTIST
-
Aron Baierlein
SCIENTIST
-
Birgit Jäckels
OFFICE MANAGER
-
Dr. Christos Kontos
SENIOR SCIENTIST
-
Dr. Evi Meier
SENIOR SCIENTIST
-
Florian Märkl
SENIOR SCIENTIST
-
Heike Url
RESEARCH ASSISTANT
-
Dr. Janet Peper-Gabriel
HEAD OF PRECLINICAL DEVELOPMENT
-
Dr. Laura Mateyka
SENIOR SCIENTIST
-
Dr. Marc-Dominic Bohn
SENIOR SCIENTIST
-
Melanie Wendl
SCIENTIST
-
Nhi Pham
SCIENTIST
-
Nicolas Quilitz
SCIENTIST
-
Nikolina Blazevic
SCIENTIST
-
Dr. Pierre Stömmer
SENIOR SCIENTIST
-
Dr. Richard Kosinski
SENIOR SCIENTIST
-
Verena Noderer
RESEARCH ASSISTANT
The Advisors
-
Prof. Dr. Hendrik Dietz
FOUNDER & ADVISOR
DNA nanotech pioneer -
Dr. Johanna Holldack
ADVISOR
Serial drug-dev entrepreneur -
Prof. Dr. Sebastian Kobold
ADVISOR
Clinical pharmacologist
